Showing 9 posts of 9 posts found.

Novartis’ Jakavi Phase 3 trial is first of its kind to hit main goal in steroid-refractory acute graft-versus-host disease

April 23, 2020
Research and Development Jakavi, Novartis, pharrma

Novartis has revealed impactful new Phase 3 data for its therapy Jakavi (ruxolitinib) in the treatment of patients with steroid-refractory …

Novartis presents strong results in rare blood disorder trials

June 10, 2016
Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder

Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …


Incyte to stop Jakafi pancreatic, colorectal cancer drug trials

February 11, 2016
Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …

Jakavi image

Novartis blood cancer drug given EU nod

March 17, 2015
Sales and Marketing Cancer, EU, Jakavi, Novartis, oncology, polycythemia vera, ruxolitinib

Novartis’ blood cancer drug Jakavi has been given the green light in Europe to treat adult patients with polycythemia vera …

Novartis image

Novartis earns EMA and FDA nods for Jakavi and Bexsero

January 26, 2015
Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib

Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …

NICE image

NICE rejects Jakavi

February 13, 2013
Sales and Marketing Jakavi, NICE

NICE has today issued draft guidance saying it does not recommend Novartis’ Jakavi for patients with myelofibrosis, a rare blood …

Novartis’ 2012 results flat

January 24, 2013
Sales and Marketing Bexsero, Jakavi, Novartis, generics, results

Generic competition has put a dent in Novartis’ financial results for 2012, with net sales down 3% year on year …


Novartis blood cancer hope

December 12, 2012
Research and Development, Sales and Marketing Jakavi, Novartis, oncology

Two-year data from Novartis’s drug Jakavi suggests that it may improve overall survival in a rare form of cancer versus …

Novartis’ myelofibrosis treatment approved in Europe

August 28, 2012
Sales and Marketing Incyte, Jakavi, Novartis, Orphan Drugs, myelofibrosis

Novartis’ Jakavi, a new treatment for patients with myelofibrosis has been approved in Europe. The drug was co-developed with Incyte, …

Latest content